Levacetylleucine Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 310 mg, 500 mg
Reference Brands: Tanganil(USA)
Category:
Neurology
Levacetylleucine is available in Tablets
and strengths such as 310 mg, 500 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Levacetylleucine is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Levacetylleucine can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Levacetylleucine, also known as N-acetyl-L-leucine and marketed under the brand name Aqneursa, is an orally administered medication used for the treatment of neurological manifestations associated with Niemann-Pick disease type C. It is the L-enantiomer of acetylleucine, a modified form of the amino acid leucine, which allows for improved bioavailability and targeted neurological activity. Levacetylleucine is believed to modulate neuronal function and enhance central nervous system stability, helping to reduce symptoms such as ataxia, imbalance, and impaired coordination. Its oral formulation provides a convenient administration route, making it suitable for long-term management of neurological symptoms in patients with Niemann-Pick disease type C. By supporting neuronal function, levacetylleucine contributes to improved mobility, daily functioning, and overall quality of life for affected individuals.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing